TCM
PAVM icon

Traynor Capital Management’s PAVmed PAVM Stock Holding History

Traynor Capital Management’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22
Closed -$9K – 191
2022
Q2 		$9K Sell
22
-9
-29% -$4.35K ﹤0.01% 174
2022
Q1 		$18K Buy
+31
New +$23K ﹤0.01% 198

Other funds holding PAVM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Traynor Capital Management's PAVM Position: Q3 2022 in Review

Traynor Capital Management sold out of PAVmed (PAVM) in Q3 2022, closing a stake of 22 shares — an estimated $9K sold.

Traynor Capital Management first reported a position in PAVM in Q1 2022 and held it in 2 quarters. The position peaked at $18K in Q1 2022. 70 funds tracked by Wall St. Rank hold PAVM as of Q3 2022.

  • Traynor Capital Management reported no remaining PAVmed position as of Q3 2022 after selling out during the quarter.
  • Traynor Capital Management sold 22 PAVmed shares in Q3 2022, an estimated $9K.
  • Traynor Capital Management first reported a position in PAVmed in Q1 2022 and held it in 2 quarters.
  • Traynor Capital Management's PAVmed position peaked at $18K in Q1 2022.
  • 70 funds tracked by Wall St. Rank held PAVmed as of Q3 2022.

Based on Traynor Capital Management's 13F filing for Q3 2022, filed 20 Oct 2022.